MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -875.52% | -1,336.26% | -563.65% | 56.12% | 84.82% |
| Total Depreciation and Amortization | -198.27% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,299.44% | 2,801.52% | 710.10% | -48.19% | -83.38% |
| Change in Net Operating Assets | 335.90% | 577.58% | 439.61% | -103.42% | -81.87% |
| Cash from Operations | -945.77% | -378.63% | -27.68% | 68.85% | 93.33% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 93.69% | 93.69% | 26.19% | 80.86% | 80.86% |
| Issuance of Common Stock | 771.82% | -- | -- | -56.28% | -85.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.14% | -100.00% | -100.00% |
| Cash from Financing | 900.85% | 2,164.96% | 55.72% | -83.32% | -89.11% |
| Foreign Exchange rate Adjustments | 70.18% | 70.18% | 70.18% | -138.87% | -138.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,298.42% | 85.32% | 58.15% | -497.64% | 38.51% |